Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Combining a statin not metabolized by cytochrome P450 3A4 (CYP3A4) with the antibiotic clarithromycin is associated with an increased risk of adverse events, according to the results of a new analysis. Individuals taking rosuvastatin (Crestor, AstraZeneca), pravastatin, or fluvastatin with clarithromycin had a 65% increased risk of hospitalization for acute kidney injury, a more than two-fold increased risk of hyperkalemia, and a 43% increased risk of all-cause mortality compared with individuals taking non-CYP3A4-metabolized statins and azithromycin[1].
The absolute increase in the risk of adverse events was small—less than 1%. Still, researchers say the "modest increase" in the number of deaths and hospital admissions among the older adults studied may reflect statin toxicity.
http://www.medscape.com/viewarticle/837315
(free registration required)
The absolute increase in the risk of adverse events was small—less than 1%. Still, researchers say the "modest increase" in the number of deaths and hospital admissions among the older adults studied may reflect statin toxicity.
http://www.medscape.com/viewarticle/837315
(free registration required)